Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Cardurion Pharmaceuticals Inc. holds a company patent portfolio with 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Prosecution is split between 2 distinct examiners. Despite the involvement of multiple examiners, all activity is contained within 1 distinct art unit. This suggests that the patent office has assigned these matters to a specific technical niche, even if different individuals are conducting the reviews.
WORSHAM, JESSICA N is the busiest examiner for this portfolio, currently holding 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, no single examiner has a majority of the workload. This distribution means that the prosecution outcomes are not dependent on 1 examiner's discretion. Practitioners must prepare for potentially different feedback styles from the 2 distinct examiners, although the shared art unit implies a common set of examination standards will apply to both pending actions. The focus on 1 distinct art unit for the entire portfolio simplifies the technical landscape.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WORSHAM, JESSICA N | 1 | 56.6% | +56.4% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18939305 | POLYMORPHS OF A PYRIDINYLIMIDAZO[1,2-B]PYRIDAZINE | LADD, CAROLYN LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18989150 | PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE | WORSHAM, JESSICA N | — |
| 18939305 | POLYMORPHS OF A PYRIDINYLIMIDAZO[1,2-B]PYRIDAZINE | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18989150 | PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE | WORSHAM, JESSICA N | 1615 | §102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18939305 | POLYMORPHS OF A PYRIDINYLIMIDAZO[1,2-B]PYRIDAZINE | LADD, CAROLYN LOUISE | — | §102§103§112 | Non-Final OA | — | Pending | Nov 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCardurion Pharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Jessica N Worsham has the most, with 1 of Cardurion Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
